Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy

SARS-CoV-2 对接受免疫治疗的患者临床病程和 NK 细胞的影响

• 批准号: 10203557
• 负责人: Nina Bhardwaj
• 金额: $ 16.84万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10203557
• 关键词: 2019-nCoV; Affect; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; COVID-19; Cancer Patient; Cell Compartmentation; Cells; Cessation of life; Clinical; Clinical/Radiologic; Data; Disease; Functional disorder; Immune checkpoint inhibitor; Immune system; Immunotherapy; Individual; Infection; Malignant Neoplasms; Metastatic Melanoma; Natural Killer Cells; PD-1 blockade; Patients; Phenotype; Pneumonia; Population; Radiologic Finding; Recording of previous events; Recovery; Regimen; Resolution; Severities; Solid Neoplasm; T-Lymphocyte; Tumor Suppression; Virus Diseases; cancer immunotherapy; chemotherapy; cohort; exhaust; exhaustion; experience; high risk; melanoma; palliation; pandemic disease; peripheral blood; programmed cell death protein 1; receptor; response

The pandemic caused by SARS-CoV-2 has killed 430,000 people worldwide in the span of 6 months which overall place cancer patients at a higher risk of severe illness and death if infected, although differences between distinct therapy regimens are possible (e.g. chemotherapy vs. immunotherapy vs. palliation). Cancer patients who have recovered from COVID-19 may need to resume treatment, including immunotherapy for their disease even though the repercussions of this infection on their immune systems are unknown. This project will determine if cancer patients who have recovered from COVID-19 have NK cells with different functionality than cancer patients who were not infected, and whether these phenotypes have an impact on the overall response rate and survival of this population.

由SARS-COV-2引起的大流行在6个月的时间内丧生全球43万人 如果感染了总体癌症患者的严重疾病和死亡风险较高，尽管 可能的治疗方案是可能的（例如，化学疗法与免疫疗法与抑制）。癌症患者 从COVID-19恢复的人可能需要恢复治疗，包括针对其疾病的免疫疗法 即使这种感染对免疫系统的影响尚不清楚。这个项目将确定 如果从COVID-19的癌症患者患有与癌症功能不同的NK细胞 未被感染的患者，以及这些表型是否对总体反应率和 这个人群的生存。

项目成果

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.

• DOI: 10.1038/s41467-018-05992-x
• 发表时间: 2018-08-29
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Wang L;Saci A;Szabo PM;Chasalow SD;Castillo-Martin M;Domingo-Domenech J;Siefker-Radtke A;Sharma P;Sfakianos JP;Gong Y;Dominguez-Andres A;Oh WK;Mulholland D;Azrilevich A;Hu L;Cordon-Cardo C;Salmon H;Bhardwaj N;Zhu J;Galsky MD
• 通讯作者: Galsky MD

Harnessing Natural Killer Cell Function for Genitourinary Cancers.

• DOI: 10.1016/j.ucl.2020.07.002
• 发表时间: 2020-11
• 期刊: The Urologic clinics of North America
• 作者: Bhardwaj N;Farkas AM;Gul Z;Sfakianos JP
• 通讯作者: Sfakianos JP

TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer.

• DOI: 10.1016/j.urolonc.2020.06.007
• 发表时间: 2022-09
• 期刊: Urologic oncology
• 作者: Attalla K;Farkas AM;Anastos H;Audenet F;Galsky MD;Bhardwaj N;Sfakianos JP
• 通讯作者: Sfakianos JP